Update date: February 1, 2024

Group No. 18: Family Planning

DESOGESTREL

Clue	Description	Indications	Route of administration and dosage
010.000.2212.00	TABLET Each tablet contains: Desogestrel 0.075 mg Package with 28 tablets.	Contraception. Pregnancy prevention.	Oral. Adults: 0.075 mg every 24 hours.

Generalities

The contraceptive effect of Desogestrel is achieved by inhibiting ovulation and from the absence of both the peak of LH in the middle of the cycle as well as the increase in progesterone during the luteal phase.

Risk in Pregnancy x

Adverse effects

Headache, nausea, acne, mastalgia, irregular menstruation, amenorrhea, mood disturbance, decreased libido, weight gain.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. Known or suspected pregnancy, active venous thromboembolism, presence or history of severe liver disease while liver function values have not normalized, progestogen-dependent tumors, undiagnosed vaginal bleeding.
Precautions: Individual evaluation of the benefit / risk ratio in pre-existing breast cancer and in women diagnosed with breast cancer during the use of Desogestrel.

Interactions

Interactions have been identified with the concomitant use of hydantoins, barbiturates, primidone, carbamazepine, rifampicin, oxcarbamazepine, rifabutin, troglitazone, felbamate and griseofulvin.

DESOGESTREL AND ETHINYLESTRADIOL

Clue	Description	Indications	Route of administration and dosage
010.000.3505.00	TABLET Each tablet contains: Desogestrel 0.15 mg Ethinyl estradiol 0.03 mg Package with 21 tablets.	Contraception. Pregnancy prevention.	Oral. Adults: One tablet daily at night from the fifth day of the menstrual cycle.

Generalities

Synthetic progestogen with estrogen that inhibits ovulation and modifies the genital tract, preventing the union of germ cells.

Risk in Pregnancy x

Adverse effects

Nausea, vomiting, headache, nervousness, intermenstrual bleeding, amenorrhea, scant and short-lasting menstruation.

Contraindications and Precautions

Contraindications: Hypersensitivity to drugs, history or presence of breast tumors, liver disease, systemic arterial hypertension, thromboembolic disease, diabetes mellitus, smoking women for more than 35 years old.

Interactions

Rifampicin, ampicillin, tetracycline, chloramphenicol, benzodiazepines and barbiturates decrease the contraceptive effect.

ETONOGESTREL

Clue	Description	Indications	Route of administration and dosage

010.000.3510.00	IMPLANT The implant contains: Etonogestrel 68.0 mg Package with an implant and applicator.	Contraception. Pregnancy prevention.	Subcutaneous. Adults: One implant every three years. Insert it from day 1 to 5 of the menstrual cycle. Insertion and removal should be carried out by an experienced doctor.

Generalities

Association of synthetic progestogen with estrogen that inhibits ovulation and modifies the genital tract, preventing the union of germ cells.

Risk in Pregnancy x

Adverse effects

Nausea, vomiting, headache, nervousness, intermenstrual bleeding, amenorrhea, scant and short-lasting menstruation.

Contraindications and Precautions

Contraindications: Hypersensitivity to drugs, history or presence of breast tumors, liver disease, systemic arterial hypertension, thromboembolic disease, diabetes mellitus, smoking women for more than 35 years old.

Interactions

Rifampicin, ampicillin, tetracycline, chloramphenicol, benzodiazepines and barbiturates decrease the contraceptive effect.

LEVONORGESTREL

Clue	Description	Indications	Route of administration and dosage
010.000.2210.00	TABLET OR TABLET Each tablet or tablet contains: Levonorgestrel 0.750 mg Package with 2 tablets or tablets.	Postcoital contraception.	Oral. Women of childbearing age, including adolescents: A tablet or tablet. Take as soon as possible after unprotected sexual intercourse, and at the latest within 72 hours. Take a second tablet or tablet 12 hours after the first. If vomiting occurs within 3 hours after the first dose, take the second tablet or tablet immediately.
010.000.6075.00	IMPLANT Each implant contains: Levonorgestrel 75.0 mg Package with 2 implants and a box with a trocar and attached instructions	Contraception	Subcutaneous Adults: Two implants every 5 years, must be inserted within 7 days after the start of menstrual bleeding.

Generalities

Levonorgestrel is a synthetic progestogen that modifies ovarian function, produces an increase in the density of cervical mucus and, consequently, prevents the passage of sperm to the uterus. It also suppresses endometrial activity and can prevent blastocyst implantation.

Risk in Pregnancy x

Adverse effects

Headache, nervousness, dizziness, nausea, changes in menstrual pattern (frequent, irregular or prolonged menstrual bleeding, spotting, amenorrhea), cervicitis, vaginal discharge, genital itching, pelvic pain, breast pain, weight gain.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. Known or suspected pregnancy. Active venous thromboembolic disease, presence or history of severe liver disease as long as liver function values have not returned to normal. Presence or history of liver tumors (benign or malignant). Suspected or certain malignant neoplasms dependent on sex hormones. Undiagnosed vaginal bleeding.

Precautions: Patients with a history of thromboembolic disease should only use Levonorgestrel if other contraceptive methods are inadequate and after careful assessment of the risk/benefit ratio. Special care should be observed when prescribing Levonorgestrel implants to patients with known risk factors for, or predisposition to, venous arterial disease. In patients with a history of or who develop focal or progressive migraine, or with worsening of migraine during the use of Levonorgestrel, the situation should be carefully evaluated. Contact lens users who develop vision changes or intolerance should be evaluated by an ophthalmologist. The patient may be advised to stop using these lenses, either for some time or permanently.

Interactions

The effect of hormonal contraceptives may be affected by medications that induce hepatic enzymes, as this could cause a decrease in the contraceptive effect, including primidone, barbiturates, phenytoin, carbamazepine, rifampicin, oxacarbazepine, griseofulvin and “St. Juan” *(Hypericum perforaturm).*

LEVONORGESTREL AND ETHINYLESTRADIOL

Clue	Description	Indications	Route of administration and dosage
010.000.3504.00	DRAGEE Each dragee contains: Levonorgestrel 0.15 mg Ethinylestradiol 0.03 mg Container with 21 dragees.	Contraception. Pregnancy prevention.	Oral. Adults: One daily dragee at night from the fifth day of the menstrual cycle.
010.000.3507.00	DRAGEE Each dragee contains: Levonorgestrel 0.15 mg Ethinylestradiol 0.03 mg Container with 28 dragees. (21 with hormonal and 7 without hormonal).		

Generalities

Association of progestin with estrogen that inhibits ovulation and modifies the genital tract, preventing the union of germ cells.

Risk in Pregnancy

x

Adverse effects

Amenorrhea, dysfunctional uterine bleeding, nausea, vomiting, headache, nervousness, scanty and short-lived menstruation.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, history or presence of breast tumors, liver disease, diabetes mellitus, thromboembolic disease, systemic arterial hypertension, smoking women over 35 years of age.

Interactions

Rifampicin, ampicillin, tetracycline, chloramphenicol, benzodiazepines and barbiturates decrease the contraceptive effect.

MEDROXYPROGESTERONE AND ESTRADIOL CYPIONATE

Clue	Description	Indications	Route of administration and dosage
010.000.3509.00	INJECTABLE SUSPENSION Each vial or syringe contains: Medroxyprogesterone acetate 25 mg Estradiol cypionate 5 mg Package with a 0.5 mL prefilled vial or syringe.	Contraception. Pregnancy prevention.	Deep intramuscular. Adults: First time; administer a vial or syringe between the first and fifth day of the menstrual cycle. Second time, administer one month after the first dose.

Generalities

Association of synthetic progestogen with estrogen that inhibits ovulation and modifies the genital tract, preventing the union of germ cells.

Risk in Pregnancy x

Adverse effects

Nausea, vomiting, intermenstrual bleeding, amenorrhea, headache, depression, thrombophlebitis and thromboembolic disorders, chloasm

to.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, estrogen-dependent or breast neoplasms, thromboembolic and liver disease, diabetes, epilepsy, asthma and mental illness, undiagnosed vaginal bleeding.

Interactions

Rifampicin, ampicillin, tetracycline, chloramphenicol, benzodiazepines and barbiturates decrease the contraceptive effect.

NORELGESTROMINE-ETHINYLESTRADIOL

Clue	Description	Indications	Route of administration and dosage
010.000.3511.00	PATCH Each patch contains: Norelgestromin 6.00 mg Ethinyl estradiol 0.60 mg Package with 3 patches.	Contraception. Pregnancy prevention.	Cutaneous. Adults: Apply a patch every week, preferably on the same day, for 3 weeks. Leave a week without patch. Each patch delivers 150 µg of norelgestromin and 20 µg of ethinyl estradiol every 24 hours.

Generalities

It acts through the gonadotropin suppression mechanism, through the estrogenic and progestational actions of ethinyl estradiol and norelgestromin. The primary mechanism of action is inhibition of ovulation, but alterations in cervical mucus, fallopian tube motility, and endometrium may also contribute to effectiveness.

Risk in Pregnancy x

Adverse effects

Benign liver tumors and carcinoma; cervical and breast cancer; pituitary adenomas with prolactin. Neuro-ocular injuries. Myocardial infarction, migraine, high blood pressure, strokes, deep vein thrombosis, arterial and pulmonary thromboembolism. Intrahepatic cholestasis and cholelithiasis. Reaction at the application site. Fluid retention, change in body weight, lower glucose tolerance. Mood swings, depression, irritability, changes in libido. Estrogen-induced chorea. Change in the curvature of the cornea. Nausea, vomiting, spasms and abdominal distention. Erythema nodosum, pruritus, rash, chloasma, erythema multiforme, acne, seborrhea, alopecia.
Intermenstrual bleeding, amenorrhea, change in size of uterine fibromyomas, vaginal candidiasis, dysmenorrhea, mastodynia, galactorrhea.

Contraindications and Precautions

Contraindications: Hypersensitivity to any component of this product. History or conditions such as acute thrombophlebitis and thromboembolic disorders. Cerebrovascular or coronary artery disease. Valvular heart disease with complications and severe arterial hypertension. Diabetes with vascular complications. Migraine with focal aura. Carcinoma of the breast, endometrium or other type of estrogen-dependent tumor. Abnormal genital bleeding. Cholestatic jaundice of pregnancy or with previous use of hormonal contraceptives. Acute or chronic hepatocellular disease with failure. Liver adenomas or carcinomas.
Precautions: Risk of pregnancy in obese women weighing more than 90 kg. In population at risk of arterial thromboembolic conditions and kidney failure.

Interactions

Rifampicin, ampicillin, tetracycline, chloramphenicol, benzodiazepines and barbiturates decrease the contraceptive effect. With St. John's wort, risk of pregnancy or intermenstrual bleeding and metrorrhagia. With viral protease inhibitors, circulating levels of hormones are modified; indinavir increases them and ritonavir decreases them.

NORETHISTERONE AND ESTRADIOL

Clue	Description	Indications	Route of administration and dosage
		Contraception.	Deep intramuscular.

010.000.3515.00	INJECTABLE SOLUTION Each vial or syringe contains: Norethisterone enanthate 50 mg Estradiol valerate 5 mg Container with a vial or syringe with one mL.		Adults: Administer a vial or syringe within the first 5 days of the menstrual cycle. Subsequently every 30 ÿ 3 days, regardless of the menstrual cycle.

Generalities

Combination of progestogen with estrogen that prevents ovulation by inhibiting the secretion of pituitary gonadotropins and producing changes in cervical mucus and endometrial mucosa.

Risk in Pregnancy x

Adverse effects

Nausea, vomiting, mastalgia, weight gain, headache, menstrual disorders, chloasma, depression and thrombophlebitis.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, history of breast and liver cancer, heart failure.
Precautions: In systemic arterial hypertension, diabetes mellitus, epilepsy and bronchial asthma.

Interactions

Ampicillin, rifampicin, tetracycline and anticonvulsants decrease its contraceptive effect.

CETROELIX

Clue	Description	Indications	Route of administration and dosage
010.000.4210.00	INJECTABLE SOLUTION The vial with lyophilisate contains: Cetrorelix acetate equivalent to 0.25 mg of cetrorelix. Package with a vial and 1 mL syringe with diluent.	Prevention of Premature ovulation during controlled ovarian stimulation.	Subcutaneous. Adults: Dosage at the discretion of the specialist and according to the therapeutic response.
010.000.4211.00	INJECTABLE SOLUTION The vial with lyophilisate contains: Cetrorelix acetate equivalent to 3.0 mg of cetrorelix. Package with a vial and 3 mL syringe with diluent.		

Generalities

Gonadotropin-releasing hormone agonist, it competes with it for the membrane receptors of the pituitary cells.

Risk in Pregnancy d

Adverse effects

Occasionally nausea, headache and ovarian hyperstimulation syndrome.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, menopause, moderate and severe alterations in liver and kidney function.

Interactions

None of clinical importance.

FOLLITROPIN BETA

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Contraception.	Subcutaneous:

010.000.4142.00	Each vial with solution contains: Follitropin beta 50 IU Container with a vial bottle with 0.5 mL.	Defective follicular maturation.	Adults: 50 IU per day for 7 days.

Generalities

Recombinant FSH produced by DNA technology.

Risk in Pregnancy C

Adverse effects

Hematoma, redness, edema and burning at the application site. Ovarian hyperstimulation in 5%. Increased risk of ectopic and multiple pregnancies. Rarely arterial thrombosis.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, ovarian, breast, uterus, pituitary or hypothalamus tumors, inflammation of the sexual organs, pregnancy.
Precautions: Non-gonadal endocrinopathies.

Interactions

With clomiphene citrate you can increase the follicular response.

LEVONORGESTREL

Clue	Description	Indications	Route of administration and dosage
010.000.2208.00	DUST The device with powder contains: Levonorgestrel (micronized) 52 mg. Container with a device.	Contraception. Menorrhagia treatment.	Intrauterine. Adults: 52 mg periodically at the discretion of the specialist.
010.000.6160.00	DUST The powdered intrauterine device contains: Levonorgestrel 19.5 mg Package with an intrauterine device.	Contraception in multiparous and nulliparous women.	Intrauterine. Adults: It should be placed in the uterine cavity in any of the 7 days following the start of menstruation for up to 5 years.

Generalities

Progestogen that inhibits pituitary gonadotropic secretion, follicular maturation and forms a thick cervical mucus.

Risk in Pregnancy X

Adverse effects

Headache, abdominal/pelvic pain, acne/seborrhea, changes in menstrual bleeding, including increased or decreased menstrual bleeding, dripping, oligomenorrhea and amenorrhea, ovarian cyst and vulvovaginitis.

Contraindications and Precautions

Contraindications: pregnancy; acute or recurrent pelvic inflammatory disease; or conditions related to an increased risk of pelvic infections; Cervicitis or acute vaginitis; postpartum endometritis or infected abortion during the last three months; neoplasia of the cervix; uterine or cervical malignancy; progestogen-dependent tumors; abnormal uterine bleeding of unknown etiology; congenital or acquired uterine anomaly including fibroids that interfere with the placement and/or retention of the intrauterine system (i.e. if they deform the uterine cavity); acute liver disease or liver tumor, hypersensitivity to the active substance or to any of the excipients.
Precautions: Migraine, focal migraine with asymmetric vision loss or other symptoms indicative of transient cerebral ischemia. Exceptionally severe headache, jaundice and marked increase in blood pressure, severe arterial disease such as e.g. Stroke or myocardial infarction.

Interactions

Drugs that induce microsomal enzymes, phenytoin, barbiturates, pidone, carbamazepine, rifampicin, and possibly also oxcarbazepine, topiramate, felbamate, griseofulvin, and products containing St. John's wort.

LINESTRENOL

Clue	Description	Indications	Route of administration and dosage
010.000.4527.00	TABLET Each tablet contains: Linestrenol 0.50 mg. Package with 28 tablets.	Contraception.	Oral. Adult: One tablet per day, without interruptions, during the period in which you wish to avoid pregnancy.

Generalities

Low-dose contraceptive preparation of the progestin-only type, it acts on cervical mucus, in the endometrium it prevents nidation due to suppression of LH, in the middle of the cycle and due to the absence of an increase in progesterone, it inhibits ovulation and the formation of the corpus luteum.

Risk in Pregnancy x

Adverse effects

Intermenstrual bleeding, postmedication amenorrhea, breast hypersensitivity, nausea, vomiting, cholelithiasis, high blood pressure, thrombosis, chloasma, rash, headache, fluid retention, changes in body weight.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, history or severe liver disease, history of jaundice during pregnancy or due to steroid use, undiagnosed vaginal bleeding, severe pruritus during pregnancy.

Interactions

Irregular bleeding and decreased contraceptive reliability may occur with anticonvulsants, barbiturates, rifampicin, activated charcoal, and certain laxatives. It decreases glucose tolerance and increases the need for oral hypoglycemic agents.

NORETHISTERONE

Clue	Description	Indications	Route of administration and dosage
010.000.3503.00	OIL INJECTABLE SOLUTION Each vial contains: Norethisterone enanthate 200 mg Container with a 1 mL vial.	Contraception. Pregnancy prevention.	Deep intramuscular. Adults: One vial every two months, in the first days of the menstrual cycle.

Generalities

Synthetic progestin that blocks pituitary gonadotropic secretion mechanisms and modifies cervical mucus.

Risk in Pregnancy x

Adverse effects

Amenorrhea, dysfunctional uterine bleeding, nausea, vomiting, headache, weight gain, application site pain, nervousness.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, breast tumors, liver disease, thromboembolic disease, diabetes mellitus, high blood pressure, smoking women over 35 years of age.

Interactions

Rifampin decreases the effects of progestins.

PROGESTERONE

Clue	Description	Indications	Route of administration and dosage
010.000.4207.00	GEL Each applicator contains: Progesterone 90 mg Container with 6 applicators.	Benign mastopathy. Mastalgia and mastodynia.	Cutaneous in mammary gland. Adults: Apply a quarter of the gel from 1 applicator (22.5 mg) to the affected mammary gland, daily.

			Duration of treatment at the discretion of the specialist.

Generalities

Progesterone applied locally in the mammary gland is distributed and disseminated throughout the adipose tissue to treat and prevent the vascular and cellular effects caused by a progesterone deficiency at the level of the breasts, suspending the increase in capillary permeability, tissue hydration. connective tissue, the stimulation and differentiation of the galactophore epithelium, blocking rapid epithelial mitotic activity and the formation of glandular acini.

Risk in Pregnancy

b

Adverse effects

Skin rash at application sites.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, malignant processes and women under 12 years of age.

Interactions

None of clinical importance.